Navigation Links
Ore Pharmaceutical Holdings Announces Name Change and Reverse/Forward Stock Split to be Effective June 10, 2011
Date:6/6/2011

CAMBRIDGE, Mass., June 6, 2011 /PRNewswire/ -- Ore Pharmaceutical Holdings Inc. ("Ore") announced today that, pursuant to the authorization granted by the stockholders of Ore, the Board of Directors of Ore (the "Board") approved and authorized a 1-for-10,000 reverse stock split (the "Reverse Stock Split") of Ore's common stock, $0.01 par value (the "Common Stock"), such that stockholders owning fewer than the amount necessary to receive at least one share of post-split Common Stock (the "Cashed Out Stockholders"), and remaining stockholders holding fractional shares after the Reverse Stock Split, will have such pre-split shares cancelled and converted into the right to receive certain cash consideration, immediately followed by a 10,000-for-1 forward stock split of the Common Stock (the "Forward Stock Split" and together with the Reverse Stock Split, the "Reverse/Forward Stock Split"). The Reverse/Forward Split is expected to be effective June 10, 2011. It is anticipated that the Common Stock will begin trading on the Pink Sheets on a post-split basis at the opening of trading on June 13, 2011 under its current symbol "ORXE.PK".

As previously announced, at the 2011 Annual Meeting of Stockholders of Ore, stockholders approved a name change of Ore from "Ore Pharmaceutical Holdings Inc." to "Ore Holdings, Inc." Ore intends to effect the name change concurrently with the Reverse/Forward Stock Split.

No fractional shares of Common Stock will be issued as a result of the implementation of the Reverse/Forward Split.  Instead, BNY Mellon, our transfer agent, will aggregate all fractional shares of Cashed Out Stockholders and any fractional shares of remaining stockholders after the Reverse/Forward Split and sell them as soon as practicable after the effective time at the then prevailing prices on the open market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share.  We expect that the transfer agent will conduct the sale in an orderly fashion at a reasonable pace and that it may take at least several days to sell all of the aggregated fractional shares of our Common Stock.  After the transfer agent's completion of such sale, stockholders will be entitled to receive a cash payment from the transfer agent in an amount equal to their respective pro rata shares of the total net proceeds of that sale.

Ore intends to treat shares of Common Stock held by stockholders in "street name," that is, through a bank, broker or other nominee, in the same manner as stockholders whose shares of Common Stock are registered in their names.  Banks, brokers and nominees will be asked to effect the Reverse/Forward Split for the underlying beneficial owners holding the Common Stock in "street name."  However, these banks, brokers and nominees may have different procedures for processing the Reverse/Forward Split.  Stockholders who hold their shares in "street name" should ask their broker, nominee or agent to determine how they expect the Reverse/Forward Split will affect their shares of Common Stock. Please refer to the Proxy Statement relating to the 2011 Annual Meeting of Stockholders that was previously mailed to stockholders for more information regarding the Reverse/Forward Stock Split.

As previously reported, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue to provide quarterly and annual financial information by posting such information on its web site, www.orepharma.com.

To ensure the preservation of the Company's net operating loss, our Certificate of Incorporation limits the ability of stockholders from acquiring more than five percent of our outstanding stock.

Ore Pharmaceutical Holdings Inc. is currently focused on developing and monetizing its current portfolio of pharmaceutical assets, which includes four clinical stage compounds in-licensed from major pharmaceutical companies.


'/>"/>
SOURCE Ore Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. Onyx Pharmaceuticals to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
3. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
4. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
6. Vanda Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
7. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
10. Isis Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
11. Jazz Pharmaceuticals Announces Presentation at the Jefferies 2011 Global Healthcare Conference in New York on June 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):